H3 receptor antagonists/inverse agonists as anti-obesity agents

Current Opinion in Investigational Drugs

Volumn 4, Issue 10, 2003, Pages 1190-1197

  Hancock, Arthur A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antagonist; H3 receptor; Histamine; Inverse agonist; Obesity

Indexed keywords

1 (4 CHLOROPHENYL) 4 (4 CYCLOPENTYLPIPERAZIN 1 YL)BUTANE 1,4 DIONE; 2 IMIDAZOL 4 YLCYCLOPROPYL(CYCLOHEXYLMETHOXY)CARBAMIDE; 4 (6 CYCLOHEX 3 ENYL)IMIDAZOLE; 4 [2 (5,5 DIMETHYLHEX 1 YNYL)CYCLOPROPY]IMIDAZOLE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 4' [3(DIMETHYLAMINO)PYRROLIDINYL 1 YL)PROPOXY]BIPHENYL 4 CARBONITRILE; A 331440; ALPHA FLUOROMETHYLHISTIDINE; ANTIHISTAMINIC AGENT; ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPHENIRAMINE; CIPROXIFAN; DEXFENFLURAMINE; GT 2227; GT 2331; GT 2394; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR AGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR; HISTAMINE RECEPTOR; HISTIDINE; LEPTIN; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; PROPRANOLOL; THIOPERAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; HISTAMINE AGONIST;

APPETITE; BODY WEIGHT; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM FUNCTION; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEEDING BEHAVIOR; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; NONHUMAN; OBESITY; PROTEIN LOCALIZATION; REVIEW; SIDE EFFECT; SKIN ALLERGY; ULCER; WEIGHT GAIN; ANIMAL; EATING; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; ANTI-OBESITY AGENTS; EATING; HISTAMINE; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; NEURONS; NEUROTRANSMITTER AGENTS; RECEPTORS, HISTAMINE H3;

EID: 0242658587     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Hauner H: Current pharmacological approaches to the treatment of obesity. Int J Obesity Relat Metab Disord (2001) 25(Suppl 1):S102-S106.
2. Yanovski SZ, Yanovski JA: Obesity. N Engl J Med (2002) 346(5):591-602.
3. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M: Histaminergic transmission in the mammalian brain. Physiol Rev (1991) 71(1):1-51. A basic, but thorough review of the important neurotransmitter role of histamine in the CNS.
4. 3 receptors in a thorough monograph.
5. Onodera K, Yamatodani A, Watanabe T, Wada H: Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Prog Neurobiol (1994) 42(6):685-702.
6. Brown RE, Stevans DR, Haas HL: The physiology of brain histamine. Prog Neurobiol (2001) 63(6):637-672.
7. 3 receptor antagonists act at a single site? Eur J Pharmacol (2001) 431(2):215-221.
8. Hough LB: Genomics meets histamine receptors: New subtypes, new receptors. Mol Pharmacol (2001) 59(3):415-419. An excellent brief overview of the four histamine receptor subtypes.
9. 4R. Biochem Biophys Res Commun (2000) 279(2):615-620.
10. 3 receptor. Mol Pharmacol (1999) 55(6):1101-1107.
11. 2 receptor in monkey brain and its mRNA localization in monkey and human brain. Synapse (2000) 38(3):343-354.
12. 3 receptor and its gene transcripts in rat brain. Neuroscience (2002) 114(1):173-193.
13. 3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis (2001) 8(4):707-716.
14. Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP, Tominaga M, Goto K, Shioda S, Sakurai T: Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun (2002) 290(4):1237-1245.
15. 3 Receptor. Leurs R, Timmerman H (Eds), Elsevier, Amsterdam, the Netherlands (1998):13-26.
16. 3 receptors.
17. 3 receptor. Neuropharmacology (2002) 42(7):929-940.
18. 3 receptor: Gene organization and multiple isoforms. Biochem Biophys Res Comm (2001) 280(1):75-80.
19. 3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol (2001) 59(1):1-8.
20. 3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther (2000) 293(3):771-778.
21. 3 receptors: Role of two amino acids in the third transmembrane domain. Br J Pharmacol (2000) 131(7):1247-1250.
22. 3 receptor heterogeneity. Neuropharmacology (2003) 44(6):773-786.
23. 4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther (2001) 299(1):121-130.
24. 3 receptors.
25. 3 receptors. Br J Pharmacol (2002) 135(2):383-392.
26. 3 antagonists. J Pharmacol Exp Ther (2001) 299(3):908-914.
27. Vaziri P, Dang K, Anderson GH: Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. J Nutr (1997) 127(8):1519-1526.
28. Sakata T, Ookuma K, Fujimoto K, Fukagawa K, Yoshimatsu H: Histaminergic control of energy balance in rats. Brain Res Bull (1991) 27(3-4):371-375.
29. 3 receptors and the pharmacology of its ligands. Nihon Shinkei Seishin Yakurigaku Zasshi (1995) 15:87-102.
30. Sakata T, Yoshimatsu H, Kurokawa M: Hypothalamic neuronal histamine: Implications of its homeostatic control of energy metabolism. Nutrition (1997) 13(5):403-411.
31. Sakata T: Histamine receptor and its regulation of energy metabolism. Obesity Res (1995) 3(Suppl 4):541-548.
32. Sakata T, Yoshimatsu H: Homeostatic maintenance regulated by hypothalamic neuronal histamine. Methods Find Exp Clin Pharmacol (1995) 17(Suppl C):51-56.
33. Yoshimatsu H, Chiba S, Tajima D, Akehi Y, Sakata T: Histidine suppresses food intake through its conversion into neuronal histamine. Exp Biol Med (2002) 227(1):63-68.
34. Morimoto T, Yamamoto Y, Mobarakeh JI, Yanai K, Watanabe T, Watanabe T, Yamatodani A: Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav (1999) 67(5):679-683.
35. Toftegaard CL, Knigge U, Kjaer A, Warberg J: The role of hypothalamic histamine in leptin-induced suppression of short-term food intake in fasted rats. Regul Pept (2003) 111(1-3):83-90.
36. Lecklin A, Hermonen P, Tarhanen J, Mannisto PT: An acute i.c.v. infusion of leptin has no effect on hypothalamic histamine and tele-methylhistamine contents in Wistar rats. Eur J Pharmacol (2000) 395(2):113-119.
37. Morimoto T, Yamamoto Y, Yamatodani A: Brain histamine and feeding behavior. Behav Brain Res (2001) 124(2):145-150.
38. Yoshimatsu H, Itateyama E, Kondou S, Tajima D, Himeno K, Hidaka S, Kurokawa M, Sakata T: Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes (1999) 48(12):2286-2291.
39. Morimoto T, Yamamoto Y, Yamatodani A: Leptin facilitates histamine release from the hypothalamus in rats. Brain Res (2000) 868(2):367-369.
40. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T: Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes (2001) 50(2):376-384.
41. 1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes (2001) 50(2):385-391.
42. 1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol - Regulat Integrat Comparat Physiol (2001) 281(5):R1442-R1448.
43. 1 receptors in the ventromedial hypothalamus mediate the anorectic action of the pancreatic hormone amylin. Peptides (2003) 24(1):155-158.
44. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry (1999) 60(6):358-363.
45. McIntyre RS, Mancini DA, Basilee VS: Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry (2001) 62(Suppl 23):23-29.
46. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL: Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry (2001) 62(Suppl 23):45-66.
47. 3 receptor expression during rat development and in adult rat peripheral tissues. Abstr Soc Neurosci (2001) 27:Abs 3789.
48. Yoshimatsu H, Hidaka S, Niijima A, Sakata T: Histamine neurons down-regulate ob gene expression in rat white adipose tissue. Inflamm Res (2001) 50(Suppl 2):S72-S73.
49. Tsuda K, Yoshimatsu H, Niijima A, Chiba S, Okeda T, Sakata T: Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. Exp Biol Med (2002) 227(3):208-213.
50. 3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci (2001) 69(4):469-478.
51. 3 receptor antagonist, suppressed NPY-but not dynorphin A-induced feeding in rats. Regul Pept (1998) 75-76:373-376.
52. 3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol Psychiatry (1999) 45(4):475-481.
53. Ookuma K, Sakata T, Fukugawa K, Yoshimatsu H, Kurokawa M, Fujimoto K: Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res (1993) 628(1-2):235-242.
54. Merali Z, Banks K: Does the histaminergic system mediate bombesin/GRP-induced suppression of food intake? Am J Physiol (1994) 267(6 Pt 2):R1589-R1595.
55. 3 receptor knockout animal phenotypic behaviors.
56. 3 knockout mice from the perspective of an obese phenotype.
57. 3 receptor antagonists, A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther (2003) 305(3):897-908.
58. 3-antagonist, A-349821 {4′-[3-(2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-biphenyl-4-yl}-morpholin-4- yl-methanone. FASEB J (2003) 17:Abs 3701.
59. 3 receptor antagonist thioperamide is described.
60. Bray GA: A concise review on the therapeutics of obesity. Nutrition (2000) 16(10):953-960.
61. Bjenning C, Johannesson U, Juul A-G, Lange KZ, Rimvall K: Peripherally administered ciproxifan elevates hypothalamic histamine levels and potently reduces food intake in the Sprague Dawley rat. Abstracts of the International Sendai Histamine Meeting, Sendai, Japan (2000) P-39:144.
62. 3 antagonist ciproxifan to blunt feeding behavior.
63. 3 receptor antagonist, GT-2394 on food intake and weight gain in Sprague-Dawley rats. Abstr Soc Neurosci (2000) 26:Abs 102.10.
64. Yates SL, Powlowski GP, Babu JS, Rajagopalan R, Wawro WJ, Tedford CE: Inverse agonists of the histamine-3 receptor as appetite suppressants. ACS (2003) 225:MEDI2. A description of the pharmacology of GT-2394 and other similar antagonists, with an emphasis on a hypothetical link between inverse agonist activity and anti-obesity activity.
65. Crow S, Brown E: Investigational drugs for eating disorders. Expert Opin Investig Drugs (2003) 12(3):491-499.
66. 3 receptors. Eur J Pharmacol (2002) 453(1):33-41.
67. 3 antagonists.
68. 3 antagonists. Archiv Pharm (1999) 332(11):389-398.
69. 3 receptor antagonists. J Med Chem (2000) 43(12):2362-2370.
70. 3-receptor antagonists. Eur J Pharm Sci (2001) 13(3):249-259.
71. 3-receptor ligands. Part I. Bioorg Med Chem Lett (2002) 12(15):2031-2034.
72. 3-receptor ligands. Part II: Binding preference for D-amino-acid motifs. Bioorg Med Chem Lett (2002) 12(15):2035-2037.
73. 3 antagonists. Bioorg Med Chem Lett (2002) 12(21):3055-3058.
74. Faghih R, Dwight W, Vasudevan A, Dinges J, Conner SE, Esbenshade TA, Bennani YL, Hancock AA: Animoalkoxybiphenylnitriles as histamine-3 receptor ligands. Bioorg Med Chem Lett (2002) 12(21):3077-3079. The synthesis and structure-activity relationships of A-331440 and related compounds are described.
75. 3 receptor antagonists. Bioorg Med Chem Lett (2003) 13(7):1325-1328.
76. 3-receptor antagonists: Synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines. Bioorg Med Chem Lett (2003) 13(13):2131-2135.
77. 3-receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol (2003) 367(1):43-50.
78. Lin JH, Lu AYH: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet (1998) 35(5):361-390. This paper describes an important link between imidazole-based compounds and potential drug-drug interactions.
79. Slater JW, Zechnich AD, Haxby DG: Second-generation antihistamines. A comparative review. Drugs (1999) 57(1):31-47. This paper describes an important link between imidazole-based compounds and potential drug-drug interactions.
80. 3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology (2002) 66(3):128-135. This paper describes important linkage between imidazole-based compounds and potential drug-drug interactions.
81. 3-receptor antagonist, thioperamide, in rats. II Farmaco (1997) 52(6-7):457-462.
82. 125I]iodophenpropit binding. Brain Res (1996) 743(1-2):178-183.
83. 3 receptor antagonist A-331440 decreases body weight in male C57BL/6J mice with high fat diet-induced obesity. Am Diabetes Assoc (2002):1715-P. First presentation of the anti-obesity properties of A-331440 in diet-induced obesity in mice.
84. 3 receptor antagonist, A-331440. IUPHAR, Pharmacologist (2002) 44(Suppl 1):A196.
85. 3 receptor antagonist with favorable effects in diet-induced obesity in mice. Abstr Soc Neurosci (2002) 28:Abs 869.10.
86. 3 receptor antagonists exemplified by A-331440. Emerging targets for the treatment of obesity. ACS (2003) 225:MEDI3.
87. 3 receptor antagonist, A-331440. IUPHAR, Pharmacologist (2002) 44(Suppl 1):A157.
88. 3 antagonists in models of obesity. Eur Histamine Res Soc, Noordwijkerhout, the Netherlands (2003):82.
89. 3-adrenergic agonist BRL-37344 (BRL) on body weight, food intake and metabolic rate in obese (ob/ob) mice. FASEB J (2003) 17:3763.
90. 3 receptor antagonist.
91. Bays H, Dujovne C: Anti-obesity drug development. Expert Opin Investig Drugs (2002) 11(9):1189-1204.
92. Finer N: Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab (2002) 16(4):717-742.
93. Crowley VEE, Yeo GSH, O'Rahilly S: Obesity therapy: Altering the energy intake-and-expenditure balance sheet. Nat Rev Drug Disc (2002) 1(4):276-286.
94. Nisoli E, Carruba MO: New pharmacological tools for obesity. J Endocrinol Invest (2002) 25(10):905-914.